• Neoadjuvant pembrolizumab outperforms it as adjuvant in resectable melanoma

    Compared with the same treatment given entirely in the adjuvant setting, this application improves event-free survival in resectable stage III–IV melanoma patients.

  • Improved survival seen with pembrolizumab + CRT in locally advanced head-and-neck SCC

    First-line pembrolizumab plus chemoradiotherapy shows favourable trend to improved EFS in locally advanced head and neck squamous cell carcinoma.

  • Sotorasib shows superior PFS and ORR over docetaxel in previously treated NSCLC

    Improvement seen in progression-free survival and ORR by the selective KRAS G12C inhibitor over docetaxel in previously treated KRAS G12C-mutated NSCLC.

  • Abemaciclib: OS benefit in HR-positive / HER2-negative ABC still statistically insignificant

    Overall survival seems numerically longer with abemaciclib + NSAI in post-menopausal patients with HR-positive / HER2-negative advanced breast cancer.

  • TILs identify patients with immunogenic triple-negative breast cancer

    Patients with TNBC with over 40% Tumour Infiltrating Lymphocytes in their tumour, respond well on neoadjuvant immune checkpoint blockade.

  • Triple therapy improves PFS in aRCC versus dual therapy

    Cabozantinib/ nivolumab/ipilimumab improves progression-free survival versus dual nivolumab/ipilimumab in untreated advanced renal cell carcinoma.

  • Nivolumab + ipilimumab: No improved survival in local RCC at high risk post-nephrectomy

    Phase 3 Checkmate 914 trial showed that the adjuvant treatment does not improve survival for stage II–III localised RCC, which has high post-nephrectomy risk.

  • Advanced melanoma: Tumour-infiltrating lymphocytes outperform ipilimumab

    Second-line treatment with TIL improves PFS compared with ipilimumab in patients with advanced, non-resectable stage III–IV melanoma.

  • Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

    Addition of enzalutamide to AAP does not improve overall survival of metastatic hormone-sensitive prostate cancer patients, STAMPEDE trial results show.

  • OS benefit in ovarian cancer patients treated with maintenance olaparib

    Addition of maintenance olaparib to bevacizumab provides clinically meaningful overall survival benefit in patients who are HRD-positive.

  • Pathway from air pollution to lung cancer in non-smokers identified

    Increasing exposure to 2.5 µm particulate matter increases the risk of non-small cell lung cancer in non-smoking individuals with EGFR mutations.

  • Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

    Final study analysis did not show benefit in advanced hepatocellular carcinoma, but lenvatinib's role as standard first-line treatment in aHCC was supported.

  • Deep learning predicts relapse and mutational profile risks in GIST

    Deep learning from digitalised haematoxylin and eosin-stained whole-tumour slide images outperformed classical Miettinen relapse risks prediction.

  • High responses to neoadjuvant immune checkpoint inhibition in local dMMR colon cancer

    Treatment with nivolumab/ipilimumab for 4 weeks achieved a major pathological response in 95% of patients with stage III dMMR colon cancer.

  • Fruquintinib: a potential treatment option for refractory mCRC patients

    A trial demonstrated a doubling of PFS and a near doubling of overall survival with the VEGF-1, -2, and -3 inhibitor in patients with refractory mCRC.

  • The ESMO Congress 2022 - we meet again

    None